Answers to Everyday Practice Challenges in HIV Medicine
The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature.
Carvalho AF, Sharma MS, Brunoni AR, et al. Psychother Psychosom. 2016;85(5):270-288.
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Lancet HIV. 2017;4(9):e384-e392.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Cutrell AG, Schapiro JM, Perno CF, et al. AIDS. 2021;35(9):1333–1342.
Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults With HIV.
DeHaan E, McGowan JP, Fine SM, et al, for the Medical Care Criteria Committee of the New York State Department of Health AIDS Institute. Baltimore, MD: Johns Hopkins University; 2021.
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.
Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.
Ford S, Crauwels H, Han K, et al. CROI. Virtual Conference; March 8-11, 2020. Abstract 466.
Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.
Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-95.
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.
Hoffmann C, Welz T, Sabranski M, et al. HIV Med. 2017;18(1):56-63.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S, Brummel SS, Ziemba L, et al. Lancet. 2021;397(10281):1276-1292.
Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.
Transgender women's concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs).
Rael CT, Martinez M, Giguere R, et al. AIDS Behav. 2020;24(5):1452-1462.
Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.
Radix A, Sevelius J, Deutsch MB. J Int AIDS Soc. 2016;19(suppl 2):20810.
Depression and anxiety disorders: benefits of exercise, yoga, and meditation.
Saeed SA, Cunningham K, Bloch RM. Am Fam Physician. 2019;99(10):620-627.
Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.
Segal-Maurer S, Castagna A, Berhe M, et al. CROI. Virtual Conference; March 6-10, 2021. Abstract 127.
Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.
Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.
Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):185-186.
Clinical Practice Guidelines
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.
Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.
US Department of Health and Human Services
Standards of care for the health of transsexual, transgender, and gender-nonconforming people.
World Professional Association for Transgender Health.
Patient and Caregiver Resources
aidsmap resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Clinician Resources
ASCVD Risk Estimator Plus.
American College of Cardiology
Calculating total daily dose of opioids for safer dosage.
Centers for Disease Control and Prevention
HIV drug resistance database.
Stanford University
UCSF Transgender Care.
University of California, San Francisco.
Long-Acting Injectables
Module 1
| Faculty: | David Malebranche, MD, MPH; Raphael J. Landovitz, MD, MSC |
| Release: | 10/18/2021 |
| Expiration: | 10/18/2022 |
Adolescents and Young Adults Newly Diagnosed with HIV
Module 2
| Faculty: | David Malebranche, MD, MPH; David C. Griffith, MD |
| Release: | 10/18/2021 |
| Expiration: | 10/18/2022 |
HIV in Women
Module 3
| Faculty: | Chloe Orkin, MBBCH, MSc, FRCP; Sharon L. Walmsley, MSc, MD, FRCPC |
| Release: | 11/01/2021 |
| Expiration: | 11/01/2022 |
Heavily Treatment-Experienced Patients
Module 4
| Faculty: | Chloe Orkin, MBBCH, MSc, FRCP; Jonathan Schapiro, MD |
| Release: | 11/01/2021 |
| Expiration: | 11/01/2022 |
Controversies in Managing Resistance
Module 5
| Faculty: | Richard A. Elion, MD; Jürgen Rockstroh, MD |
| Release: | 11/15/2021 |
| Expiration: | 11/15/2022 |
Neuropsychological and Cognitive Changes
Module 6
| Faculty: | Richard A. Elion, MD; Glenn Jordan Treisman, MD, PhD |
| Release: | 11/15/2021 |
| Expiration: | 11/15/2022 |
Substance Use Disorder
Module 7
| Faculty: | Richard A. Elion, MD; Andrew Kolodny, MD |
| Release: | 11/29/2021 |
| Expiration: | 11/29/2022 |
Implicit Bias and Racial Disparities
Module 8
| Faculty: | David Malebranche, MD, MPH; Oni Blackstock, MD, MHS |
| Release: | 12/13/2021 |
| Expiration: | 12/13/2022 |
Transgender Patient
Module 9
| Faculty: | David Malebranche, MD, MPH; Asa Radix, MD, PhD, MPH, FACP |
| Release: | 01/03/2022 |
| Expiration: | 01/03/2023 |
Weight Gain and Other Adverse Events
Module 10
| Faculty: | Richard A. Elion, MD; Todd T. Brown, MD, PhD |
| Release: | 01/17/2022 |
| Expiration: | 01/17/2023 |
Intersection of COVID-19 and HIV
Module 11
| Faculty: | Sharon L Walmsley, MSc, MD, FRCPC; Karine Lacombe, MD, PhD |
| Release: | 01/24/2022 |
| Expiration: | 01/24/2023 |
Cardiovascular Disease
Module 12
| Faculty: | Sharon L Walmsley, MSc, MD, FRCPC; Priscilla Hsue, MD |
| Release: | 01/31/2022 |
| Expiration: | 01/31/2023 |
